A Phase 1 interventional study of ALG-000184 and Placebo in Healthy Participants, sponsored by Aligos Therapeutics. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Aligos Therapeutics · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A Phase 1 trial of ALG-000184 in healthy participants to assess the safety and tolerability of single and multiple (if applicable) oral doses of ALG-000184 (Part A and B) and ALG-001075 Following a Single Oral Dose of [14C]ALG-000184 and a Single Intravenous Dose of [13C7,15N1]ALG-001075 (Part C)
Aligos Therapeutics is the lead sponsor of 16 studies on the registry; 1 is open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 2 (29%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria: Key Inclusion Criteria
Exclusion Criteria: Key Exclusion Criteria:
Parts A and B only: Any of the following at screening or check-in:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral tablet(s) of placebo in HV participants once daily for up to 10 days
Drug: ALG-000184
Oral tablet(s) of placebo in HV participants once daily for up to 10 days
Drug: Placebo
Radiation: [14C]ALG-000184 · Radiation: [13C7,15N1]ALG-001075
Single or multiple doses of ALG-000184
Single or multiple doses of Placebo
Single oral dose of \[14C\]ALG-000184
Single micodose of \[13C7,15N1\]ALG-001075 with combination of \[14C\]ALG-000184
Safety and Tolerability (Part A and B)
Number of participants with Incidence and severity of adverse events, 12-lead electrocardiogram parameters, and abnormal clinical laboratory results
Time frame: From enrollment to end of treatment at 10 days
PK Parameters (Part A and B)
PK parameters of ALG-001075 and ALG-000302, including AUC0-∞
Time frame: From enrollment to end of treatment at 10 days
PK Parameters (Part A and B)
PK parameters of ALG-001075 and ALG-000302, including AUC0-tlast
Time frame: From enrollment to end of treatment at 10 days
PK Parameters (Part A and B)
PK parameters of ALG-001075 and ALG-000302, including AUC0-τ
Time frame: From enrollment to end of treatment at 10 days
PK Parameters (Part A and B)
PK parameters of ALG-001075 and ALG-000302, including Cmax
Time frame: From enrollment to end of treatment at 10 days
PK Parameters (Part A and B)
PK parameters of ALG-001075 and ALG-000302, including tmax t1/2
Time frame: From enrollment to end of treatment at 10 days
PK Parameters (Part A and B)
PK parameters of ALG-001075 and ALG-000302, including ARAUC
Time frame: From enrollment to end of treatment at 10 days
Total radioactivity recovery (fet1-t2) in urine and feces (Part C)
determine the routes, rates of elimination, and mass balance of total radioactivity following a single oral dose of \[14C\]ALG-000184
Time frame: From enrollment to end of treatment at 10 days
Metabolic profiles of ALG-000184 (Part C)
Determine, where possible, the metabolite profiles in plasma, urine, and feces following administration of \[14C\]ALG-000184
Time frame: From enrollment to end of treatment at 10 days
Identification of ALG-000184 (Part C)
Determine, where possible, the chemical structure of major metabolites in plasma, urine, and feces following administration of \[14C\]ALG-000184
Time frame: From enrollment to end of treatment at 10 days
Bioavailability of ALG-001075 (Part C)
Determine the absolute bioavailability of ALG-001075 following oral administration of \[14C\]ALG-000184 relative to IV administration of \[13C7,15N1\]ALG-001075
Time frame: From enrollment to end of treatment at 10 days
PK parameters (Part C)
PK parameters for ALG-001075 and \[13C7,15N1\]ALG-001075 in plasma and total radioactivity in plasma and whole blood including AUC0-∞
Time frame: From enrollment to end of treatment at 10 days
PK parameters (Part C)
PK parameters for ALG-001075 and \[13C7,15N1\]ALG-001075 in plasma and total radioactivity in plasma and whole blood including AUC0-tlast
Time frame: From enrollment to end of treatment at 10 days
PK parameters (Part C)
PK parameters for ALG-001075 and \[13C7,15N1\]ALG-001075 in plasma and total radioactivity in plasma and whole blood including Cmax
Time frame: From enrollment to end of treatment at 10 days
PK parameters (Part C)
PK parameters for ALG-001075 and \[13C7,15N1\]ALG-001075 in plasma and total radioactivity in plasma and whole blood including tmax
Time frame: From enrollment to end of treatment at 10 days
PK parameters (Part C)
PK parameters for ALG-001075 and \[13C7,15N1\]ALG-001075 in plasma and total radioactivity in plasma and whole blood including t1/2
Time frame: From enrollment to end of treatment at 10 days
QTc (Part A and B)
Evaluate the effect of single and multiple (if applicable) oral doses of ALG-000184 on QTc in healthy participants
Time frame: From enrollment to end of treatment at 10 days
Safety and Tolerability (Part C)
Number of participants with Incidence and severity of adverse events, 12-lead electrocardiogram parameters, and abnormal clinical laboratory results
Time frame: From enrollment to end of treatment at 10 days
Start is estimated for Dec 2026; primary completion for Aug 2027, 7 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aligos Therapeutics